PRNewsWire
19 Nov 2026, 07:06 UTC · 12h ago
Evotec and Bristol Myers Squibb Advance Strategic Protein Degradation Partnership with Second IND Acceptance
Impact · against what's priced in
The second IND acceptance for the Evotec-BMS partnership provides a modest positive catalyst by demonstrating the repeatable productivity of Evotec's platform and advancing BMY's molecular glue pipeline. While typical for these collaborations, the milestone payment and pipeline progression offer incremental upside to revenue and asset valuation.
- EVO+0.40
No priced-in read yet





